<!DOCTYPE html>
<html class="no-js">
  <head>
    <meta charset="utf-8" />
    <meta http-equiv="X-UA-Compatible" content="IE=edge" />
    <title>MELANOMA</title>
    <meta name="viewport" content="width=device-width, initial-scale=1" />
    <meta name="description" content="Cáncer Genitourinario" />
    <meta name="keywords" content="oncologia, medicina" />
    <meta name="author" content="e-oncologia" />

    <link rel="shortcut icon" type="image/png" href="images/logopeque.png" />

    <link
      href="https://fonts.googleapis.com/css?family=Open+Sans&display=swap"
      rel="stylesheet"
    />
    <link
      href="https://fonts.googleapis.com/css?family=Montserrat:400,700"
      rel="stylesheet"
      type="text/css"
    />

    <link rel="stylesheet" href="css/animate.css" />
    <link rel="stylesheet" href="css/icomoon.css" />
    <link rel="stylesheet" href="css/bootstrap.css" />
    <link rel="stylesheet" href="css/owl.carousel.min.css" />
    <link rel="stylesheet" href="css/owl.theme.default.min.css" />
    <link rel="stylesheet" href="css/style.css" />
    <script src="js/modernizr-2.6.2.min.js"></script>
  </head>

  <body>
    <div id="ico-page">
      <a href="#" class="js-ico-nav-toggle ico-nav-toggle"><i></i></a>

      <aside
        id="ico-aside"
        role="complementary"
        class="border js-fullheight"
        style="background-image: url(images/BGoscuro.jpg)"
      >
        <p><br /></p>
        <h2 id="ico-logo">
          <a href="index.html"><img src="images/logo.png" height="80" /></a>
        </h2>
        <nav id="ico-main-menu" role="navigation">
          <ul>
            <li>
              <a href="m1u0.html"
                ><span class="bgdestacado2">PRESENTACIÓN</span></a
              >
            </li>
            <br />
            <li>
              <a href="m1u1a.html"
                ><span class="bgdestacado2">MÓDULO 1</span
                ><br />EPIDEMIOLOGÍA</a
              >
            </li>

            <br />
            <li>
              <a href="m2u1a.html"
                ><span class="bgdestacado2">MÓDULO 2</span><br />MELANOMA
                LOCALIZADO DE ALTO RIESGO</a
              >
            </li>
            <br />
            <li>
              <a href="m3u1a.html"
                ><span class="bgdestacado2">MÓDULO 3</span><br />MELANOMA
                METASTÁSICO</a
              >
            </li>
            <br />
            <li>
              <a href="m4u1a.html"
                ><span class="bgdestacado2">MÓDULO 4</span><br />MELANOMA
                EXTRACUTÁNEO</a
              >
            </li>
            <br />
            <li>
              <a href="m5u1.html"
                ><span class="bgdestacado1 gris">GLOSARIO</span></a
              >
            </li>
            <br />
            <li>
              <a href="m6u1.html"
                ><span class="bgdestacado1 gris">BIBLIOGRAFÍA</span></a
              >
            </li>
          </ul>
        </nav>
      </aside>

      <div id="ico-main">
        <div class="ico-cabeceraVERDE">
          <div class="ico-narrow-content animate-box">
            <h4 class="text-center blanco">Bibliografía</h4>
            <img
              src="images/ICONObiblio.png"
              alt=""
              class="img-responsive centrada"
            />
          </div>
        </div>

        <div class="ico-narrow-content">
          <div class="row animate-box" data-animate-effect="fadeInLeft">
            <div class="col-md-12">
              <h1></h1>
            </div>
          </div>
        </div>
        <div class="ico-narrow-content">
          <div class="row animate-box" data-animate-effect="fadeInLeft">
            <div class="col-md-12">
              <div class="col-md-3">
                <a href="#1"
                  ><div class="marcoTexto">
                    <h5 class="centrado">módulo 1</h5>
                  </div></a
                >
              </div>
              <div class="col-md-3">
                <a href="#2"
                  ><div class="marcoTexto">
                    <h5 class="centrado">módulo 2</h5>
                  </div></a
                >
              </div>

              <div class="col-md-3">
                <a href="#3"
                  ><div class="marcoTexto">
                    <h5 class="centrado">módulo 3</h5>
                  </div></a
                >
              </div>
              <div class="col-md-3">
                <a href="#4"
                  ><div class="marcoTexto">
                    <h5 class="centrado">módulo 4</h5>
                  </div></a
                >
              </div>
            </div>
          </div>
        </div>
        <div class="ico-narrow-content">
          <div class="row animate-box" data-animate-effect="fadeInLeft">
            <div class="col-md-12">
              <img class="centrada" src="images/ICONOclic.png" alt="" />
              <p class="centrado negrita">
                Haz click para acceder directamente a la bibliografía específica
                de cada tema
              </p>
              <br />
              <br /><br />
              <br /><br />
              <p></p>
            </div>
          </div>
        </div>
        <div class="ico-franja">
          <div class="ico-narrow-content animate-box">
            <div class="row">
              <div class="col-md-12">
                <h3 id="1">
                  MÓDULO 1: Epidemiología, factores de riesgo, histopatología y
                  biología molecular
                </h3>
                <p class="marcoOSCURO">
                  <span class="verde">Gorbe C, Leiter U. </span>Melanoma
                  epidemiology and trends. Clin Dermatol. 2009; 27:3-9.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde">Marks R. </span>Epidemiology of melanoma.
                  Clin Exp Dermatol. 2000; 25:459-63.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde">Saenz S,Conejo-Mir J and Cayuela A. </span
                  >Melanoma epidemiology in Spain. Actas Dermosifiliogr,
                  2005;96:411-8.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Marcos-Gragera R, Vilar-Coromina N, Galceran J. </span
                  >Rising trends in incidence of cutaneous malignant melanoma
                  and their future projections in Catalonia, Spain: Increasing
                  impact or future epidemic? J Eur Acad Dermatol Venereol,
                  2010;24:1083-85.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde">Desmond RA, Soong SJ. </span>Epidemiology
                  of malignant mela-noma. Surg Clin North Am. 2003; 83:1-29.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Schmid-Wendtner MH, Berking C, Baumert J, Schmidt M, Sander
                    CA, Plewig G, Volkenandt M.</span
                  >
                  Cutaneous melanoma in childhood and adolescence: an analysis
                  of 36 patients. J Am Acad Dermatol. 2002; 46:874-9.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde">MacKie RM. </span>Risk factors for the
                  development of pri-mary cutaneous malignant melanoma. Dermatol
                  Clin. 2002; 20:597-600.
                </p>
                <p class="marcoOSCURO">
                  <a
                    href="https://gco.iarc.fr/today/data/factsheets/cancers/17-Non-melanoma-skin-cancer-fact-sheet.pdf"
                    target="_blank"
                    >GLOBOCAN 2018 melanoma
                    <span class="icon-external-link"></span
                  ></a>
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Sociedad Española de Oncología Médica (SEOM).</span
                  >
                  Las cifras del cáncer en España SEOM 2019. Depósito Legal:
                  M-3800-2019© 2019.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Gandini S, Sera F, Cattaruzza MS, Pasquini P, Picconi O,
                    Boyle P, et al.
                  </span>
                  Meta-analysis of risk factors for cutaneous melanoma: II.Sun
                  exposure . Eur J Cancer, 2005;41:45-60.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde">Balch CM and Soong SJ. </span>Predicting
                  outcomes in metastatic melanoma. J Clin Oncol, 2008;26:168-9.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Sociedad Española de Calidad Asistencial (SECA) y el Grupo
                    Español de Melanoma (GEM)
                  </span>
                  <a
                    href="http://www.calidadasistencial.es/images/gestion/biblioteca/348.pdf"
                    target="_blank"
                    >Manual “La calidad en la atención a pacientes con melanoma
                    cutáneo. Expectativas de pacientes con melanoma
                    cutáneo”.<span class="icon-external-link"></span
                  ></a>
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Pizzichetta MA, Talamini R, Stanganelli I, Puddu P, Bono R,
                    Argenziano G, et al.
                  </span>
                  Amelanotic/hypomelanotic mela-noma: clinical and dermoscopic
                  features. Br J Dermatol. 2004;150: 1117-24.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde">Sagabiel R.</span> Clinical presentation.
                  En: Miller SJ, Maloney ME, editors. Cutaneous oncology.
                  Pathology, diagnosis and man-agement. Malden: Blackwell
                  Science; 1998. p.253-61.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde">Curtin JA.</span> Fridlyand J, Kageshita
                  T, et al. Distinct sets of genetic alterations in melanoma. N
                  Engl J Med. 2005;353(20):2135-2147. doi:10.1056/NEJMoa050092.
                </p>
                <p class="marcoOSCURO">
                  Genomic Classification of Cutaneous Melanoma. Cell.
                  2015;161(7):1681-1696. doi: 10.1016/j.cell. 2015.05.044.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Georgina V. Long, Alexander M. Menzies, Adnan M. Nagrial,
                    Lauren E. Haydu, Anne L. Hamilton, Graham J. Mann, T.
                    Michael Hughes, John F. Thompson, Richard A. Scolyer, and
                    Richard F. Kefford.
                  </span>
                  Prognostic and Clinicopathologic Associations of Oncogenic
                  BRAF in Metastatic Melanoma. Journal of Clinical Oncology 2011
                  29:10, 1239-1246.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Liu W, Hill D, Gibbs AF, Tempany M, Howe C, Borland R, et
                    al.
                  </span>
                  What features do patients notice that help to distinguish
                  between benign pigmented lesions and melanomas?: The ABCD(E)
                  rule versus the seven-point checklist. Melanoma Res
                  ,2005;15:549-54.
                </p>
              </div>
            </div>
          </div>
        </div>
        <div class="ico-franja">
          <div class="ico-narrow-content animate-box">
            <div class="row">
              <div class="col-md-12">
                <h3 id="2">
                  MÓDULO 2: Diagnóstico, tratamiento y seguimiento del melanoma
                  localizado y de alto riesgo
                </h3>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >GD.L. Morton, J.F. Thompson, A.J. Cochran, N. Mozzillo,
                    O.E. Nieweg, D.F. Roses, et al. </span
                  >Final trial report of sentinel-node biopsy versus nodal
                  observation in melanoma. N Engl J Med, 370 (2014), pp.
                  599-609.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >E. George, S.E. McClain, C.L. Slingluff, N.L. Polissar,
                    J.W. Patterson. </span
                  >Subclassification of desmoplastic melanoma: Pure and mixed
                  variants have significantly different capacities for lymph
                  node metastasis. J Cutan Pathol, 36 (2009), pp. 425-432.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >A. Mohebati, I. Ganly, K.J. Busam, D. Coit, D.H. Kraus,
                    J.P. Shah, et al.</span
                  >
                  The role of sentinel lymph node biopsy in the management of
                  head and neck desmoplastic melanoma. Ann Surg Oncol, 19
                  (2012), pp. 4307-4313.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >C. Callery, A.J. Cochran, D.J. Roe, W. Rees, S.D.
                    Nathanson, J.K. Benedetti, et al.
                  </span>
                  Factors prognostic for survival in patients with malignant
                  melanoma spread to the regional lymph nodes. Ann Surg, 196
                  (1982), pp. 69-75.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >A. Doubrovsky, R.A. Scolyer, R. Murali, P.R. McKenzie, G.F.
                    Watson, C.S. Lee, et al.</span
                  >
                  Diagnostic accuracy of fine needle biopsy for metastatic
                  melanoma and its implications for patient management. Ann Surg
                  Oncol, 15 (2008), pp. 323-332.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde">J.C. Briggs.</span>
                  Subungual malignant melanoma: A review article. Br J Plast
                  Surg, 38 (1985), pp. 174-176..
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >M.J. Sladden, C. Balch, D.A. Barzilai, D. Berg, A. Freiman,
                    T. Handiside, et al.</span
                  >
                  Surgical excision margins for primary cutaneous melanoma. Clin
                  Exp Dermatol, 36 (2011), pp. 334-335.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >G. Giudice, S. Leuzzi, F. Robusto, V. Ronghi, E. Nacchiero,
                    G. Giardinelli, et al.</span
                  >
                  Sentinel lymph node biopsy in head and neck melanoma. G Chir,
                  35 (2014), pp. 149-155.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >A. Tejera Vaquerizo, A. Fernández Orland, E. Gallego, R.
                    Castillo Muñoz, M. Mendiola Fernández, E. Herrera Ceballos.
                  </span>
                  Melanoma cutáneo y embarazo. Med Cutan Iber Lat Am, 35 (2007),
                  pp. 225-228.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >M.A. Warycha, J. Zakrzewski, Q. Ni, R.L. Shapiro, R.S.
                    Berman, A.C. Pavlick, et al.</span
                  >
                  Meta-analysis of sentinel lymph node positivity in thin
                  melanoma (≤ 1 mm),. Cancer, 115 (2009), pp. 869-879.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >C.M. Balch, S.J. Soong, T. Smith, M.I. Ross, M.M. Urist,
                    C.P. Karakousis, et al.</span
                  >
                  Long-term results of a prospective surgical trial comparing 2
                  cm vs. 4 cm excision margins for 740 patients with 1-4 mm
                  melanomas. Ann Surg Oncol, 8 (2001), pp. 101-108.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >G. Cohn-Cedermark, L.E. Rutqvist, R. Andersson, M.
                    Breivald, C. Ingvar, H. Johansson, et al.</span
                  >
                  Long term results of a randomized study by the Swedish
                  Melanoma Study Group on 2-cm versus 5-cm resection margins for
                  patients with cutaneous melanoma with a tumor thickness of
                  0.8-2.0 mm. Cancer, 89 (2000), pp. 1495-1501.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde">V.K. Sondak, G.T. Gibney.</span>
                  Surgical management of melanoma. Hematol Oncol Clin North Am,
                  28 (2014), pp. 455-470.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde">Faries et al.</span> Completion Dissection
                  or Observation for Sentinel Node Metastasis in Melanoma N Engl
                  J Med 2017.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >D Moreno, Ramírez, A Boada, L Ferrándiz, E Samaniego, G
                    Carretero, E Nagore, P Redondo, P Orti Romero, J Malvehy, R
                    Botella Estrada.</span
                  >
                  Disección ganglionar en el paciente con melanoma y metástasis
                  en el ganglio centinela: propuesta dedecisión basada en la
                  evidencia actual. Actas Dermosifiliogr. 2018.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Gershenwald JE, Scolyer RA, Hess KR, et al.</span
                  >
                  Melanoma staging: evidence-based changes in the American Joint
                  Committee on Cancer eighth edition cancer staging manual. CA
                  Cancer J Clin. 2017; doi:10.3322/caac.21409.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Kirkwood JM, Strawdeman MH, Ernstoff MS et al.</span
                  >
                  Interferon alfa-2b adjuvant therapy of high-risk resected
                  cutane-ous melanoma: the Eastern Cooperative Oncology Group
                  trial EST 1684. J Clin Oncol 1996: 14;7
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Kirkwood JM, Ibrahim JG, Sondak VK et al.</span
                  >
                  High and low-dose interferon alfa-2b in high-risk melanoma:
                  first analy-sis of Intergroup Trial E 1690/S9111/C9190. J Clin
                  Oncol 2000; 2444-2458.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Creagan ET, Dalton RJ, Ahmann DL et al. </span
                  >Randomized surgical adjuvant clinical trial of recombinant
                  interferon alfa-2a in selected patients with malignat
                  melanoma. J Clin Oncol 1995; 13: 2776-2783.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Grob JJ, Dreno B, de la Salmoniere, et al.</span
                  >
                  Randomized trial of interferon alfa-2a as adjuvant therapy in
                  resected pri-mary melanoma thicker than 1.5 mm without
                  clinically detectable node metastases. Lancet 1998;
                  351:1905-10.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Pehamberger H, Soyer P, Steiner A, et al.</span
                  >
                  Adjuvant interferon alfa-2a treatment in resected primary
                  stage II cuta-neous melanoma. J Clin Oncol 1998.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Kirkwood JM, Manola J, Ibrahim JG, et al.</span
                  >
                  Pooled analysis of four ECOG-Intergroup trials of high-dose
                  interferon alfa-2b (HDI) in 1916 patients with high-risk
                  resected cutaneous melanoma. Proc Am Soc Clin Oncol 2001,
                  20:1395.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Kirkwood JM, Ibrahim JG, Sosman JA et al. </span
                  >High dose interferon alfa-2b significantly prolongs
                  relapsed-free and ove-rall survival compared with the
                  GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III
                  melanoma: results ofIntergroup E 1694/S9512/C509801. J Clin
                  Oncol 2001; 2370-2380.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Cascinelli N, Bufalino R, Morabito A, et al. </span
                  >Results of adjuvant interferon study in WHO melanoma
                  programme. Lancet1994; 343:913-4.9. Eggermont AMM, Kleeberg
                  UR, Ruiter DJ, et al. The European Organization for Research
                  and Treatment of CancerMelanoma Group trial with more than
                  2000 patients, evaluating adjuvant therapy with low or
                  intermediate doses ofinterferon alpha-2b, in American Society
                  of Clinical 2001 Educational Book. Alexandria, VA, ASCO 2001,
                  pp88-93.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Kirkwood JM, Ibrahim JG, Lawson et al. </span
                  >High dose interferon alfa-2b does not disminish antibody
                  response to GM2vaccination in patients with resected melanoma:
                  results of the Multicenter Eastern Cooperative Oncology
                  Groupphase II trial E 2696. J Clin Oncol 2001; 19:1430-1436.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Wheatley K, Hancock B, Gore M et al. </span
                  >Interferon-alpha as adjuvant therapy for melanoma: a
                  meta-analysis of the ran-domised trials. Proc Am Soc Clin
                  Oncol 2001; 20 #1394.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde">Eggermont, A. M. Met al. (2019). </span
                  >Adjuvant ipilimumab versus placebo after complete resection
                  of stage III melanoma: long-term follow-up results of the
                  European Organisation for Research and Treatment of Cancer
                  18071 double-blind phase 3 randomised trial. European Journal
                  of Cancer, 119, 1–10. doi:10.1016/j.ejca.2019.07.001.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Berrocal A, Arance A, Castellon VE, de la Cruz L, Espinosa
                    E, Cao MG, et al.
                  </span>
                  SEOM clinical guideline for the management of malignant
                  melanoma (2017). Clin Transl Oncol. 2017 Nov 7.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Schadendorf D, Hauschild A, Santinami M, Atkinson V,
                    Mandalà M, Chiarion-Sileni V, et al.
                  </span>
                  Patient-reported outcomes in patients with resected, high-risk
                  melanoma with BRAFV600E or BRAFV600K mutations treated with
                  adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised,
                  placebo-controlled, phase 3 trial. Lancet Oncol. 2019
                  May;20(5):701–10.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Hauschild A, Dummer R, Schadendorf D, Santinami M, Atkinson
                    V, Mandalà M, et al. </span
                  >Longer Follow-Up Confirms Relapse-Free Survival Benefit with
                  Adjuvant Dabrafenib Plus Trametinib in Patients with Resected
                  BRAF V600-Mutant Stage III Melanoma. J Clin Oncol. 2018 Oct
                  22; JCO1801219.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Eggermont AM, Blank CU, Mandala M, Long GV, Atkinson V,
                    Dalle S, et al. </span
                  >. Abstract CT001: Pembrolizumab versus placebo after complete
                  resection of high-risk stage III melanoma: Efficacy and safety
                  results from the EORTC 1325-MG/Keynote 054 double-blinded
                  phase III trial. Cancer Research. 2018;78(13 Supplement):
                  CT001–CT001.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Weber J, Mandala M, Del Vecchio M, et al. </span
                  >Adjuvant nivolumab versus ipilimumab in resected stage III or
                  IV melanoma. N Engl J Med 2017;377:1824-1835.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Manuel Ramos-Casals, Julie R. Brahmer, Margaret K.
                    Callahan, Alejandra Flores-Chávez, Niamh Keegan, Munther A.
                    Khamashta, Olivier Lambotte, Xavier Mariette, Aleix Prat,
                    Maria E. Suárez-Almazor.</span
                  >
                  (2020) Immune-related adverse events of checkpoint inhibitors.
                  Nature Reviews Disease Primers 6:1.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Dummer Reinhard, Hauschild Axel, Santinami Mario, Atkinson
                    Victoria, Mandalà Mario, Kirkwood John M., Chiarion Sileni
                    Vanna, Larkin James, Nyakas Marta, Dutriaux Caroline, Haydon
                    Andrew, Robert Caroline, Mortier Laurent, Schachter Jacob,
                    Lesimple Thierry, Plummer Ruth, Dasgupta Kohinoor, Gasal
                    Eduard, Tan Monique, Long Georgina V., Schadendorf
                    Dirk.</span
                  >
                  (2020) Five-Year Analysis of Adjuvant Dabrafenib plus
                  Trametinib in Stage III Melanoma. N Engl J Med DOI:
                  10.1056/NEJMoa2005493.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >C. Longo, R. Pampena, A. Lallas, A. Kyrgidis, A. Stratigos,
                    K. Peris, C. Garbe, G. Pellacani.
                  </span>
                  (2020) Adjuvant therapy for cutaneous melanoma: a systematic
                  review and network meta‐analysis of new therapies. Journal of
                  the European Academy of Dermatology and Venereology 34:5,
                  956-966.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde">Giorgos Karakousis. </span>(2020) Adjuvant
                  therapy for melanoma: how to choose?. The Lancet Oncology
                  21:3, 319-320
                </p>
                <p class="marcoOSCURO">
                  <span class="verde">Alexander M.M. Eggermont et al. </span
                  >Adjuvant Pembrolizumab versus Placebo in Resected Stage III
                  Melanoma. N Engl J Med 2018; 378:1789-1801 DOI:
                  10.1056/NEJMoa1802357
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Lisa Zimmer, Elisabeth Livingstone, Jessica C Hassel,
                    Michael Fluck, Thomas Eigentler, Carmen Loquai, Sebastian
                    Haferkamp, Ralf Gutzmer, Friedegund Meier, Peter Mohr, Axel
                    Hauschild, Bastian Schilling, Christian Menzer, Felix
                    Kieker, Edgar Dippel, Alexander Rösch, Jan-Christoph Simon,
                    Beate Conrad, Silvia Körner, Christine Windemuth-Kieselbach,
                    Leonora Schwarz, Claus Garbe, Jürgen C Becker, Dirk
                    Schadendorf, Carola Berking, Rudolf A Herbst, Uwe M Martens,
                    Sabine Sell, Rudolf Stadler, Patrick Terheyden, Jochen
                    Utikal.</span
                  >
                  (2020) Adjuvant nivolumab plus ipilimumab or nivolumab
                  monotherapy versus placebo in patients with resected stage IV
                  melanoma with no evidence of disease (IMMUNED): a randomised,
                  double-blind, placebo-controlled, phase 2 trial. The Lancet
                  395:10236, 1558-1568.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Rozeman EA, Menzies AM, van Akkooi ACJ, et al.</span
                  >
                  Identification of the optimal combination dosing schedule of
                  neoadjuvant ipilimumab plus nivolumab in macroscopic stage III
                  melanoma (OpACIN-neo): a multicentre, phase 2, randomised,
                  controlled trial. Lancet Oncol 2019; 20:948.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Blank CU, Rozeman EA, Fanchi LF, et al. </span
                  >Neoadjuvant versus adjuvant ipilimumab plus nivolumab in
                  macroscopic stage III melanoma. Nat Med 2018; 24: 1655–1661.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Blank C, Rozeman E, Menzies A, et al. </span
                  >LBA42 OpACIN-neo: a multicenter phase II study to identify
                  the optimal neo-adjuvant combination scheme of ipilimumab
                  (IPI) and nivolumab (NIVO). Ann Oncol 2018; 29(Suppl. 8):
                  mdy424 052.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Blank CU, Reijers ILM, Pennington T, et al. </span
                  >First safety and efficacy results of PRADO: A phase II study
                  of personalized response-driven surgery and adjuvant therapy
                  after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in
                  resectable stage III melanoma. J Clin Oncol 2020; 38; 15S.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Hauschild A, Dummer R, Schadendorf D, et al. </span
                  >Longer Follow-Up Confirms Relapse-Free Survival Benefit With
                  Adjuvant Dabrafenib Plus Trametinib in Patients With Resected
                  BRAF V600-Mutant Stage III Melanoma. J Clin Oncol 2018;
                  36:3441.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Amaria RN, Reddy SM, Tawbi HA, et al. </span
                  >Neoadjuvant immune checkpoint blockade in high-risk
                  resectable melanoma. Nat Med 2018; 24: 1942.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Menzies A, Gonzalez M, Guminski A, et al. </span
                  >1220PDPhase 2 study of neoadjuvant dabrafenib+ trametinib (D
                  + T) for resectable stage IIIB/C BRAF V600 mutant melanoma.
                  Ann Oncol 2017; 28 (Suppl. 5).
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Amaria RN, Prieto PA, Tetzlaff MT, et al. </span
                  >Neoadjuvant plus adjuvant dabrafenib and trametinib versus
                  standard of care in patients with high-risk, surgically
                  resectable melanoma: a single-centre, open-label, randomised,
                  phase 2 trial. Lancet Oncol 2018; 19: 181–193.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde">Amaria R et al. </span>Neoadjuvant
                  systemic therapy in melanoma: recommendations of the
                  International Neoadjuvant Melanoma Consortium. Lancet
                  Oncology, The, 2019-07-01, Volumen 20, Número 7, Páginas
                  e378-e389.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Zimmer L, Livingstone E, Hassel JC, et al. </span
                  >Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy
                  versus placebo in patients with resected stage IV melanoma
                  with no evidence of disease (IMMUNED): a randomised,
                  double-blind, placebo-controlled, phase 2 trial. Lancet 2020;
                  395:1558.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde">C.N. Owen et al. </span>Management of
                  early melanoma recurrence despite adjuvant anti-PD-1 antibody
                  therapy. Annals of Oncology, 2020. DOI:
                  <a
                    href="https://doi.org/10.1016/j.annonc.2020.04.471"
                    target="_blank"
                    ><span class="icon-external-link"></span></a
                  >.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Meyers MO, Yeh JJ, Frank J, Long P, Deal AM, Amos KD, et
                    al.</span
                  >
                  Method of detection of initial recurrence of stage II/III
                  cutaneous melanoma: analysis of the utility of follow-up
                  staging. Ann Surg Oncol. 2009;16(4):941-7.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Podlipnik S, Carrera C, Sanchez M, Arguis P, Olondo ML,
                    Vilana R, et al.</span
                  >
                  Performance of diagnostic tests in an intensive follow-up
                  protocol for patients with American Joint Committee on Cancer
                  (AJCC) stage IIB, IIC, and III localized primary melanoma: A
                  prospective cohort study. J Am Acad Dermatol.
                  2016;75(3):516-24.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Poo-Hwu WJ, Ariyan S, Lamb L, Papac R, Zelterman D, Hu GL,
                    et al.</span
                  >
                  Follow-up recommendations for patients with American Joint
                  Committee on Cancer Stages I-III malignant melanoma. Cancer.
                  1999;86(11):2252-8.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Francken AB, Shaw HM, Accortt NA, Soong SJ, Hoekstra HJ,
                    Thompson JF.</span
                  >
                  Detection of first relapse in cutaneous melanoma patients:
                  implications for the formulation of evidence-based follow-up
                  guidelines. Ann Surg Oncol. 2007;14(6):1924-33.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Ribero S, Pampena R, Bataille V, Moscarella E, Thomas L,
                    Quaglino P, et al.</span
                  >
                  Unknown Primary Melanoma: Worldwide Survey on Clinical
                  Management. Dermatology. 2016;232(6):704-7.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Ribero S, Longo C, Dika E, Fortes C, Pasquali S, Nagore E,
                    et al.</span
                  >
                  Pregnancy and melanoma: a European-wide survey to assess
                  current management and a critical literature overview. J Eur
                  Acad Dermatol Venereol. 2017;31(1):65-9.
                </p>
              </div>
            </div>
          </div>
        </div>
        <div class="ico-franja">
          <div class="ico-narrow-content animate-box">
            <div class="row">
              <div class="col-md-12">
                <h3 id="3">
                  MÓDULO 3: Tratamiento quirúrgico, radioterápico y médico del
                  melanoma metastásico
                </h3>
                <p class="marcoOSCURO">
                  <span class="verde">Leung A. et al. </span>Surgery for Distant
                  Melanoma Metastasis. Cancer J. 2012 Mar; 18(2): 176–184. doi:
                  10.1097/PPO.0b013e31824bc981.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA,
                    Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC,
                    et al. </span
                  >Improved survival with ipilimumab in patients with metastatic
                  melanoma. N Engl J Med. 363:711–723. 2010.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K,
                    Hamid O, Patt D, Chen TT, Berman DM and Wolchok JD.
                  </span>
                  Pooled analysis of long-term survival data from phase II and
                  phase III trials of ipilimumab in unresectable or metastatic
                  melanoma. J Clin Oncol. 33:1889–1894. 2015.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Weide B, Martens A, Wistuba-Hamprecht K, Zelba H, Maier L,
                    Lipp HP, Klumpp BD, Soffel D, Eigentler TK and Garbe C. </span
                  >Combined treatment with ipilimumab and intratumoral
                  interleukin-2 in pretreated patients with stage IV
                  melanoma-safety and efficacy in a phase II study. Cancer
                  Immunol Immunother. 66:441–449. 2017.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Brohl AS, Khushalani NI, Eroglu Z, Markowitz J, Thapa R,
                    Chen YA, Kudchadkar R and Weber JS. </span
                  >A phase IB study of ipilimumab with peginterferon alfa-2b in
                  patients with unre-sectable melanoma. J Immunother Cancer.
                  4:852016.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol
                    M, Garbe C, Gogas H, Schachter J, Linette G, et al. </span
                  >Phase III randomized clinical trial comparing tremelimumab
                  with standard-of-care chemotherapy in patients with advanced
                  melanoma. J Clin Oncol. 31:616–622. 2013.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde">Wei SC, Duffy CR and Allison JP. </span
                  >Fundamental mechanisms of immune checkpoint blockade therapy.
                  Cancer Discov. 8:1069–1086. 2018.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier
                    L, Daud A, Carlino MS, McNeil C, Lotem M, et al. </span
                  >KEYNOTE-006 investigators: Pembrolizumab versus ipilimumab in
                  advanced melanoma. N Engl J Med. 372:2521–2532. 2015.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R,
                    Joshua AM, Patnaik A, Hwu WJ, Weber JS, et al. </span
                  >Association of pembrolizumab with tumor response and survival
                  among patients with advanced melanoma. JAMA. 315:1600–1609.
                  2016.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier
                    L, Daud A, Carlino MS, McNeil C, Lotem M, et al. </span
                  >Pembrolizumab versus ipilimumab for advanced melanoma: Final
                  overall survival results of a multicentre, randomised,
                  open-label phase 3 study (KEYNOTE-006). Lancet. 390:1853–1862.
                  2017.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R,
                    Wolchok JD, Hersey P, Joseph R, Weber JS, et al. </span
                  >Five-year survival outcomes for patients with advanced
                  melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol.
                  30:582–588. 2019.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Robert C, Ribas A, Schachter J, Arance A, Grob JJ, Mortier
                    L, Daud A, Carlino MS, McNeil CM, Lotem M, et al. </span
                  >Pembrolizumab versus ipilimumab in advanced melanoma
                  (KEYNOTE-006): Post-hoc 5-year results from an open-label,
                  multicentre, randomised, controlled, phase 3 study. Lancet
                  Oncol. 20:1239–1251. 2019.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L,
                    Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, et al. </span
                  >Nivolumab in previously untreated melanoma without BRAF
                  mutation. N Engl J Med. 372:320–330. 2015.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Ascierto PA, Long GV, Robert C, Brady B, Dutriaux C, Di
                    Giacomo AM, Mortier L, Hassel JC, Rutkowski P, McNeil C, et
                    al. </span
                  >Survival outcomes in patients with previously untreated BRAF
                  wild-type advanced melanoma treated with nivolumab therapy:
                  Three-year follow-up of a randomized phase 3 trial. JAMA
                  Oncol. 5:187–194. 2019.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL,
                    Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, et
                    al. </span
                  >Combined nivolumab and ipilimumab or monotherapy in untreated
                  melanoma. N Engl J Med. 373:23–34. 2015.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski
                    P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, et
                    al. </span
                  >Five-year survival with combined nivolumab and ipilimumab in
                  advanced melanoma. N Engl J Med. 381:1535–1546. 2019.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Kirchberger MC, Hauschild A, Schuler G and Heinzerling L. </span
                  >Combined low-dose ipilimumab and pembrolizumab after
                  sequential ipilimumab and pembrolizumab failure in advanced
                  melanoma. Eur J Cancer. 65:182–184. 2016.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Long GV, Atkinson V, Cebon JS, Jameson MB, Fitzharris BM,
                    McNeil CM, Hill AG, Ribas A, Atkins MB, Thompson JA, et al. </span
                  >Standard-dose pembrolizumab in combination with reduced-dose
                  ipilimumab for patients with advanced melanoma (KEYNOTE-029):
                  An open-label, phase 1b trial. Lancet Oncol. 18:1202–1210.
                  2017.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Zimmer L, Apuri S, Eroglu Z, Kottschade LA, Forschner A,
                    Gutzmer R, Schlaak M, Heinzerling L, Krackhardt AM, Loquai
                    C, et al. </span
                  >Ipilimumab alone or in combination with nivolumab after
                  progression on anti-PD-1 therapy in advanced melanoma. Eur J
                  Cancer. 75:47–55. 2017.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Long GV, Robert C, Blank C, Ribas A, Mortier L, Schachter
                    J, Middleton MR, et al. </span
                  >Outcomes in patients treated with ipilimumab after
                  pembrolizumab in KEYNOTE-006. Eur J Cancer. 72: S128–S129.
                  2017.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos
                    SJ, Khushalani NI, Lewis K, Lao CD, Postow MA, et al. </span
                  >Combined nivolumab and ipilimumab in melanoma metastatic to
                  the brain. N Engl J Med. 379:722–730. 2018.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP,
                    Wilmott JS, Edwards J, Gonzalez M, Scolyer RA, et al. </span
                  >Combination nivolumab and ipilimumab or nivolumab alone in
                  melanoma brain metastases: A multicentre randomised phase 2
                  study. Lancet Oncol. 19:672–681. 2018.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Conry RM, Westbrook B, McKee S and Norwood TG. </span
                  >Talimogene laherparepvec: First in class oncolytic
                  virotherapy. Hum Vaccin Immunother. 14:839–846. 2018..
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer
                    N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS,
                    et al. </span
                  >Talimogene laherparepvec improves durable response rate in
                  patients with advanced melanoma. J Clin Oncol. 33:2780–2788.
                  2015.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Chesney J, Puzanov I, Collichio F, Singh P, Milhem MM,
                    Glaspy J, Hamid O, Ross M, Friedlander P, Garbe C, et al. </span
                  >Randomized, open-label phase II study evaluating the efficacy
                  and safety of talimogene laherparepvec in combination with
                  ipilimumab versus ipilimumab alone in patients with advanced,
                  unresectable melanoma. J Clin Oncol. 36:1658–1667. 2018.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Ribas A, Dummer R, Puzanov I, Vander Walde A, Andtbacka
                    RHI, Michielin O, Olszanski AJ, Malvehy J, Cebon J,
                    Fernandez E, et al. </span
                  >Oncolytic virotherapy promotes intratumoral T cell
                  infiltration and improves anti-PD-1 immunotherapy. Cell.
                  174:1031–1032. 2018.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Durham NM, Nirschl CJ, Jackson CM, Elias J, Kochel CM,
                    Anders RA and Drake CG. </span
                  >Lymphocyte activation gene 3 (LAG-3) modulates the ability of
                  CD4 T-cells to be suppressed in vivo. PLoS One. 9:e1090802014.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Ascierto PA, Bono P, Bhatia S, Melero I, Nyakas MS, Svane
                    I, Larkin J, Gomez-Roca C, Schadendorf D, Dummer R, et al. </span
                  >LBA18Efficacy of BMS-986016, a monoclonal antibody that
                  targets lymphocyte activation gene-3 (LAG-3), in combination
                  with nivolumab in pts with melanoma who progressed during
                  prior anti-PD-1/PD-L1 therapy (mel prior IO) in all-comer and
                  biomarker-enriched populations. Ann Oncol. 28(Suppl 5):
                  v605–v649. 2017.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde">Das M, Zhu C and Kuchroo VK. </span>Tim-3
                  and its role in regulating anti-tumor immunity. Immunol Rev.
                  276:97–111. 2017.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Long GV, Dummer R, Hamid O, Gajewski TF, Caglevic C, Dalle
                    S, Arance A, Carlino MS, Grob JJ, Kim TM, et al. </span
                  >Epacadostat plus pembrolizumab versus placebo plus
                  pembrolizumab in patients with unresectable or metastatic
                  melanoma (ECHO-301/KEYNOTE-252): A phase 3, randomised,
                  double-blind study. Lancet Oncol. 20:1083–1097. 2019.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Harych DH, Hoch U, Langowski JL, Lee SR, Addepalli MK, Kirk
                    PB, Sheng D, Liu X, Sims PW, VanderVeen LA, et al. </span
                  >NKTR-214, an engineered cytokine with biased IL2 receptor
                  binding, increased tumor exposure, and marked efficacy in
                  mouse tumor models. Clin Cancer Res. 22:680–690. 2016.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Diab A, Haymaker C, Bernatchez C, Andtbacka RHI, Shaheen M,
                    Johnson D, Markowitz J, Puzanov I, Murthy R, Johnson DH, et
                    al. </span
                  >Intratumoral (it) injection of the TLR9 agonist tilsotolimod
                  (imo-2125) in combination with ipilimumab (ipi) triggers
                  durable responses in pd-1 inhibitor refractory metastatic
                  melanoma (rmm): results from a multicenter, phase 1/2 study.
                  Ann Oncol. 29(Suppl 8): viii442–viii466. 2018.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Milhem MM, Long GV, Hoimes CJ, Amin A, Lao CD, Conry RM,
                    Hunt J, Daniels GA, Almubarak M, Shaheen MF, et al. </span
                  >Phase 1b/2, open label, multicenter, study of the combination
                  of SD-101 and pembrolizumab in patients with advanced melanoma
                  who are naïve to anti-PD-1 therapy. J Clin Oncol. 37(Suppl
                  15): 9534. 2019.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Wiehagen KR, Girgis NM, Yamada DH, Smith AA, Chan SR,
                    Grewal IS, Quigley M and Verona RI. </span
                  >Combination of CD40 agonism and CSF-1R blockade reconditions
                  tumor-associated macrophages and drives potent antitumor
                  immunity. Cancer Immunol Res. 5:1109–1121. 2017.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Chick RC, Faries MB, Hale DF, Kemp Bohan PM, Hickerson A,
                    Vreelandc TJ, Myers JW, Cindass JL, Brown TA, et al. </span
                  >Multi-institutional, prospective, randomized, double-blind,
                  placebo-controlled phase IIb trial of the tumor lysate,
                  particle-loaded, dendritic cell (TLPLDC) vaccine to prevent
                  recurrence in high-risk melanoma patients: A subgroup
                  analysis. J Clin Oncol. 38(Suppl 5): 63. 2020.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS,
                    Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR,
                    et al. </span
                  >Durable complete responses in heavily pretreated patients
                  with metastatic melanoma using T-cell transfer immunotherapy.
                  Clin Cancer Res. 17:4550–4557. 2011.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M,
                    Liszkay G, et al. </span
                  >Overall survival in patients with BRAF-mutant melanoma
                  receiving encorafenib plus binimetinib versus vemurafenib or
                  encorafenib (COLUMBUS): a multicentre, open-label, randomised,
                  phase 3 trial. Lancet Oncol. 2018.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M,
                    Liszkay G, et al. </span
                  >Encorafenib plus binimetinib versus vemurafenib or
                  encorafenib in patients with BRAF-mutant melanoma (COLUMBUS):
                  a multicentre, open-label, randomised phase 3 trial. Lancet
                  Oncol. 2018;19(5):603-15.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Long GV, Eroglu Z, Infante J, Patel S, Daud A, Johnson DB,
                    et al. </span
                  >Long-Term Outcomes in Patients With BRAF V600-Mutant
                  Metastatic Melanoma Who Received Dabrafenib Combined With
                  Trametinib. J Clin Oncol. 2018;36(7):667-73.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Grimaldi AM, Simeone E, Ascierto PA. </span
                  >Vemurafenib plus cobimetinib in the treatment of mutated
                  metastatic melanoma: the CoBRIM trial. Melanoma Manag.
                  2015;2(3):209-15.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Ascierto PA, McArthur GA, Dreno B, Atkinson V, Liszkay G,
                    Di Giacomo AM, et al. </span
                  >Cobimetinib combined with vemurafenib in advanced
                  BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results
                  from a randomised, double-blind, phase 3 trial. Lancet Oncol.
                  2016;17(9):1248-60.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Long GV, Hauschild A, Santinami M, Atkinson V, Mandala M,
                    Chiarion-Sileni V, et al. </span
                  >Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated
                  Melanoma. N Engl J Med. 2017;377(19):1813-23.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Aya F, Fernandez-Martinez A, Gaba L, Victoria I, Tosca M,
                    Pineda E, et al. </span
                  >Sequential treatment with immunotherapy and BRAF inhibitors
                  in BRAF-mutant advanced melanoma. Clin Transl Oncol.
                  2017;19(1):119-24.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Schreuer M, Jansen Y, Planken S, Chevolet I, Seremet T,
                    Kruse V, et al. </span
                  >Combination of dabrafenib plus trametinib for BRAF and MEK
                  inhibitor pretreated patients with advanced BRAF(V600)-mutant
                  melanoma: an open-label, single arm, dual-centre, phase 2
                  clinical trial. Lancet Oncol. 2017;18(4):464-72.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Davies MA, Saiag P, Robert C, Grob JJ, Flaherty KT, Arance
                    A, et al. </span
                  >Dabrafenib plus trametinib in patients with BRAF(V600)-mutant
                  melanoma brain metastases (COMBI-MB): a multicentre,
                  multicohort, open-label, phase 2 trial. Lancet Oncol.
                  2017;18(7):863-73.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier
                    L, et al. </span
                  >Pembrolizumab versus ipilimumab for advanced melanoma: final
                  overall survival results of a multicentre, randomised,
                  open-label phase 3 study (KEYNOTE-006). Lancet.
                  2017;390(10105):1853-62.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde">Turajlic S, Gore M, Larkin J. </span>First
                  report of overall survival for ipilimumab plus nivolumab from
                  the phase III Checkmate 067 study in advanced melanoma. Ann
                  Oncol. 2018;29(3):542-3.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL,
                    Lao CD, et al. </span
                  >Combined Nivolumab and Ipilimumab or Monotherapy in Untreated
                  Melanoma. N Engl J Med. 2015;373(1):23-34.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B,
                    Hauschild A, Levchenko E, et al. </span
                  >Five-Year Outcomes with Dabrafenib plus Trametinib in
                  Metastatic Melanoma. N Engl J Med. 2019;381(7):626-36.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >McArthur GA, Stroyakovskiy D, Gogas H, et al. </span
                  >CT012 — Evaluation of atezolizumab (A), cobimetinib (C), and
                  vemurafenib (V) in previously untreated patients with BRAFV600
                  mutation-positive advanced melanoma: primary results from the
                  phase 3 IMspire150 trial. Presented at: the 2020 AACR Annual
                  Virtual Meeting I; April 27-28, 2020. Abstract CT012.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde">Pelster MS and Amaria RN. </span>Combined
                  targeted therapy and immunotherapy in melanoma: A review of
                  the impact on the tumor microenvironment and outcomes of early
                  clinical trials. Ther Adv Med Oncol. 11:17588359198308262019.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Ribas A, Hodi FS, Callahan M, Konto C and Wolchok J. </span
                  >Hepatotoxicity with combination of vemurafenib and
                  ipilimumab. N Engl J Med. 368:1365–1366. 2013.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Ribas A, Butler M, Lutzky J, Lawrence DP, Robert C, Miller
                    W, Linette WMGP, Ascierto PA, Kuzel T, Algazi AP, et al. </span
                  >Phase I study combining anti-PD-L1 (MEDI4736) with BRAF
                  (dabrafenib) and/or MEK (trametinib) inhibitors in advanced
                  melanoma. J Clin Oncol. 33(Suppl 15): 30032015.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Ribas, A.; Lawrence, D.; Atkinson, V.; Agarwal, S.; Miller,
                    W.H.; Carlino, M.S.; Fisher, R.; Long, G.V.;Hodi, F.S.;
                    Tsoi, J. </span
                  >Combined BRAF and MEK inhibition with PD-1 blockade
                  immunotherapy in BRAF-mutant melanoma.Nat. Med.2019,25,
                  936–940.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Chapman PB, Einhorn LH, Meyers ML, et al. </span
                  >Phase III multicenter randomized trial of the Dartmouth
                  regimen versus dacarbazine in patients with metastatic
                  melanoma. J Clin Oncol 17 (9): 2745-51, 1999.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Middleton MR, Grob JJ, Aaronson N, et al. </span
                  >Randomized phase III study of temozolomide versus dacarbazine
                  in the treatment of patients with advanced metastatic
                  malignant melanoma. J Clin Oncol 18 (1): 158-66, 2000.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde">Avril MF, Aamdal S, Grob JJ, et al. </span
                  >Fotemustine compared with dacarbazine in patients with
                  disseminated malignant melanoma: a phase III study. J Clin
                  Oncol 22 (6): 1118-25, 2004.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Robert C, Thomas L, Bondarenko I, et al. </span
                  >Ipilimumab plus dacarbazine for previously untreated
                  metastatic melanoma. N Engl J Med 364 (26): 2517-26, 2011.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Boutros C, Tarhini A, Routier E, et al. </span
                  >Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone
                  and in combination. Nat Rev Clin Oncol 2016;13(8):473-486.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Champiat S, Lambotte O, Barreau E, et al. </span
                  >Management of immune checkpoint blockade dysimmune
                  toxicities: a collaborative position paper. Ann Oncol
                  2016;27(4):559-574.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Haanen JBAG, Carbonnel F, Robert C, et al. </span
                  >Management of toxicities from immunotherapy: ESMO Clinical
                  Practice Guidelines for diagnosis, treatment and follow-up.
                  Ann Oncol 2017;28(suppl_4):iv119-iv142.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >June CH, Warshauer JT, Bluestone JA. </span
                  >Is autoimmunity the Achilles‘heel of cancer immunotherapy?
                  Nat Med 2017;23(5):540-547.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Kamta J, Chaar M, Ande A, Altomare DA, Ait-Oudhia S. </span
                  >Advancing Cancer Therapy with Present and Emerging
                  Immuno-Oncology Approaches. Front Oncol 2017;7: 64.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde">Long, et al. </span>Presented at ESMO
                  2019. Abstract 3661.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde">Tawbi, et al. </span>N Engl J Med 2018:
                  379;8.
                </p>
                <p class="marcoOSCURO">
                  Common Terminology Criteria for Adverse Events (CTCAE) Version
                  5.0 Published: November 27, 2017.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde">M. Majem et al. </span>SEOM clinical
                  guideline for the management of immune-related adverse events
                  in patients treated with immune checkpoint inhibitors (2019).
                  Clinical and Translational Oncology volume 22,
                  pages213–222(2020).
                </p>
              </div>
            </div>
          </div>
        </div>
        <div class="ico-franja">
          <div class="ico-narrow-content animate-box">
            <div class="row">
              <div class="col-md-12">
                <h3 id="4">
                  MÓDULO 4: Melanoma extracutáneo: melanoma de mucosas y ocular
                </h3>
                <p class="marcoOSCURO">
                  <span class="verde">Carvajal RD, Spencer SA, Lydiatt W. </span
                  >Mucosal melanoma: a clinically and biologically unique
                  disease entity. J Natl Compr Canc Netw 2012; 10:345.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Rapini RP, Golitz LE, Greer RO Jr, et al. </span
                  >Primary malignant melanoma of the oral cavity. Cancer 1985;
                  55:1543.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Sutherland CM, Chmiel JS, Henson DE, Winchester DP. J. </span
                  >Am Coll Surg 1994; 179:561.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Pandey M, Mathew A, Abraham EK, et al. </span
                  >Eur J Surg Oncol 1998; 24:303.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde">Lee SP, Shimizu KT, Tran LM, et al. </span
                  >Laryngoscope. 1994; 104:121-6.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde">Wada H, Nemoto K, Ogawa Y, et al. </span
                  >Int J Radiat Oncol Biol Phys. 2004;59: 495-50.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Christopherson K, Malyapa RS, Werning JW, et al. </span
                  >Am J Clin Oncol. 2015;38: 87-9.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Hamid O, Robert C, Ribas A, Hodi FS, Walpole E, Daud A,
                    Arance AS, Brown E, Hoeller C, Mortier L, Schachter J, Long
                    J, Ebbinghaus S, Ibrahim N, Butler M. </span
                  >Antitumour activity of pembrolizumab in advanced mucosal
                  melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006. Br J
                  Cancer. 2018 Sep;119(6):670-674. doi:
                  10.1038/s41416-018-0207-6. Epub 2018 Sep.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde">Shoushtari, Alexander et al. </span
                  >CheckMate 067: Long-term outcomes in patients with mucosal
                  melanoma. VL - 38 DOI - 10.1200/JCO.2020.38.15_suppl.10019.
                  Journal of Clinical Oncology.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde">Piulats et al. </span>Phase II study
                  evaluating ipilimumab as a single agent in the first-line
                  treatment of adult patients (Pts) with metastatic uveal
                  melanoma (MUM): The GEM-1 trial. DOI:
                  10.1200/jco.2014.32.15_suppl.9033 Journal of Clinical Oncology
                  32, no. 15_suppl (May 20, 2014) 9033-9033.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde">Albert DM, Kulkarni AD. </span>Intraocular
                  melanoma. In: DeVita VT Jr, Lawrence TS, Rosenberg SA: Cancer:
                  Principles and Practice of Oncology. 9th ed. Philadelphia, Pa:
                  Lippincott Williams & Wilkins, 2011, pp 2090-8.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Shields CL, Furuta M, Berman EL, et al. </span
                  >Choroidal nevus transformation into melanoma: analysis of
                  2514 consecutive cases. Arch Ophthalmol 127 (8): 981-7, 2009.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Heppt M.V., Heinzerling L., Kähler K.C., Forschner A.,
                    Kirchberger M.C., Loquai C., Meissner M., Meier F.,
                    Terheyden P., Schell B., et al. </span
                  >Prognostic factors and outcomes in metastatic uveal melanoma
                  treated with programmed cell death-1 or combined
                  PD-1/cytotoxic T-lymphocyte antigen-4 inhibition. Eur. J.
                  Cancer. 2017;82:56–65.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Algazi A.P., Tsai K.K., Shoushtari A.N., Munhoz R.R.,
                    Eroglu Z., Piulats J.M., Ott P.A., Johnson D.B., Hwang J.,
                    Daud A.I., et al. </span
                  >Clinical outcomes in metastatic uveal melanoma treated with
                  PD-1 and PD-L1 antibodies. Cancer. 2016;122:3344–3353.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Rodriguez J.M.P., Merino L.D.L.C., Espinosa E., Carrión
                    L.A., Algarra S.M., López-Castro R., García M.T.C., Abreu
                    D.R., Iriarte A.J.R., Jaime A.B. </span
                  >Phase II multicenter, single arm, open label study of
                  Nivolumab in combination with Ipilimumab in untreated patients
                  with metastatic uveal melanoma. Ann. Oncol.
                  2018;29:viii442–viii466.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >Khoja L, Atenafu EG, Suciu S, Leyvraz S, Sato T, Marshall
                    E, Keilholz U, Zimmer L, Patel SP, Piperno-Neumann S,
                    Piulats J, Kivelä TT, Pfoehler C, Bhatia S, Huppert P, Van
                    Iersel LBJ, De Vries IJM, Penel N, Vogl T, Cheng T,
                    Fiorentini G, Mouriaux F, Tarhini A, Patel PM, Carvajal R,
                    Joshua AM. </span
                  >Meta-analysis in metastatic uveal melanoma to determine
                  progression free and overall survival benchmarks: an
                  international rare cancers initiative (IRCI) ocular melanoma
                  study. Ann Oncol. 2019 Aug 1;30(8):1370-1380. doi:
                  10.1093/annonc/mdz176. PMID: 31150059.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >L. KhojaI et al. R.C.I. Ocular Melanoma Group.
                  </span>
                  <a
                    href="https://doi.org/10.1093/annonc/mdx377.025"
                    target="_blank"
                    >Validating prognostic models in metastatic uveal melanoma
                    (MUM), an international rare cancers initiative.
                    <span class="icon-external-link"></span></a
                  >.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde">Castet, Florian et al. </span>“Uveal
                  Melanoma, Angiogenesis and Immunotherapy, Is There Any Hope?.”
                  Cancers vol. 11,6 834. 17 Jun. 2019,
                  doi:10.3390/cancers11060834.
                </p>
                <p class="marcoOSCURO">
                  <span class="verde"
                    >J.M. Piulats Rodriguez, L. De La Cruz Merino, E. Espinosa,
                    L. Alonso Carrión, S. Martin Algarra, R. López-Castro, M.T.
                    Curiel García, D. Rodriguez Abreu, A.J. Rullan Iriarte, A.
                    Berrocal Jaime. </span
                  >Phase II multicenter, single arm, open label study of
                  Nivolumab in combination with Ipilimumab in untreated patients
                  with metastatic uveal melanoma. GEM1402.NCT02626962. Annals of
                  Oncology (2018) 29 (suppl_8): viii442-viii466.
                  10.1093/annonc/mdy289.
                </p>
              </div>
            </div>
          </div>
        </div>
        <div class="ico-cabecera">
          <div class="ico-narrow-content">
            <div class="pager">
              <br />
            </div>
          </div>
        </div>
      </div>
    </div>

    <!-- jQuery -->
    <script src="js/jquery.min.js"></script>
    <!-- jQuery Easing -->
    <script src="js/jquery.easing.1.3.js"></script>
    <!-- Bootstrap -->
    <script src="js/bootstrap.min.js"></script>
    <!-- Carousel -->
    <script src="js/owl.carousel.min.js"></script>
    <!-- Stellar -->
    <script src="js/jquery.stellar.min.js"></script>
    <!-- Waypoints -->
    <script src="js/jquery.waypoints.min.js"></script>
    <!-- Counters -->
    <script src="js/jquery.countTo.js"></script>
    <!-- MAIN JS -->
    <script src="js/main.js"></script>
    <!-- partial -->
    <script src="https://cdnjs.cloudflare.com/ajax/libs/vue/2.5.13/vue.min.js"></script>
    <script src="js/scriptdiagram.js"></script>
  </body>
</html>
